TL-895

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTL-895
Drug Alias NameTL-895
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTropomyosin-related kinase inhibitors
TargetsTropomyosin-related kinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursPrimary Myelofibrosis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTelios Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesTelios PharmaceuticalsKartos Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHematologic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A